, Volume 16, Issue 3, pp 227-233

The molecular fingerprint of cardiac dyssynchrony and cardiac resynchronization therapy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

To date, cardiac resynchronization therapy remains the only treatment that enhances systolic function while improving long-term outcome and survival. Here, we review the molecular alterations associated with dyssynchronous heart failure and their reversibility induced by cardiac resynchronization therapy. We focus upon the molecular portrait of dyssynchronous heart failure and how cardiac resynchronization therapy influences electrophysiologic, metabolic and adrenergic pathways.

This work has been supported by the Meijer-Lavino Foundation for Cardiac Research, Aalst, Belgium and by the 3M Pharma Prize (MV, JB).